Mauna Kea Technologies enrolls 200+ in new clinical study: 3 things to know

Mauna Kea Technologies has enrolled more than 200 patients in its CONTACT II clinical study.

Advertisement

Here are three things to know:

1. The study focuses on the characterization of pancreatic cysts with needle-based confocal laser endomicroscopy.

2. Mauna Kea Technologies is the creator of Cellvizio, a multidisciplinary confocal laser endomicroscopy platform.

3. Further clinical evidence of the safety and efficacy of with needle-based confocal laser endomicroscopy is expected to strengthen the CLE technology.

More articles on GI/endoscopy:
Healthmark introduces endoscope brush
AGA selects Dr. Nelson Garcia for future leaders program
5 GI physicians in the news

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.